{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-010790","form_type":"8-K","ticker":"SGMO","cik":"0001001233","company_name":"SANGAMO THERAPEUTICS, INC","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.028353+00:00","generated_at":"2026-06-04T21:58:37.365931+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024","bullets":["Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).","Cash $81.0M as of Dec 31, 2023; expects funding into Q3 2024 without additional capital.","STAC-BBB capsid showed 700-fold higher brain transduction vs AAV9 in NHPs; pain IND Q4 2024.","Fabry drug aligned with FDA on abbreviated approval pathway; EMA PRIME granted; seeking partner.","Wind down of French ops (93 roles); 2024 GAAP opex guidance $145–165M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-010790","json":"https://secwatch.observer/filing/0001628280-24-010790.json","markdown":"https://secwatch.observer/filing/0001628280-24-010790.md","text":"https://secwatch.observer/filing/0001628280-24-010790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/0001628280-24-010790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/sgmo-20240313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T21:58:37.365931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca792c83b87383309d388b78a57f951a7db29665","claim":"SANGAMO THERAPEUTICS, INC reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 13, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2023 (the “Press Release”).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001233/000162828024010790/0001628280-24-010790-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}